Logo

AUTL

Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc • NASDAQ
$1.42 ▲ 3.28% (+0.04)
Market Cap $376.59 M
52w High $3.45
52w Low $1.10
Dividend Yield 0%
P/E -1.7
Volume 1.46M
Outstanding Shares 266.14M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $21.194M ▲ $64.172M ▲ $-79.118M ▼ -373.304% ▼ $-0.3 ▼ $-64.703M ▼
Q2-2025 $20.923M ▲ $57.695M ▲ $-47.917M ▲ -229.016% ▲ $-0.18 ▲ $-56.906M ▼
Q1-2025 $8.982M ▲ $56.268M ▼ $-70.161M ▼ -781.129% ▲ $-0.26 ▼ $-55.516M ▲
Q4-2024 $29K ▲ $103.151M ▲ $-27.606M ▲ -95.193K% ▼ $-0.1 ▲ $-73.787M ▼
Q3-2024 $0 $67.653M $-82.094M 0% $-0.31 $-65.715M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $367.413M ▼ $661.947M ▼ $396.495M ▲ $265.452M ▼
Q2-2025 $454.279M ▼ $720.981M ▼ $374.517M ▼ $346.464M ▼
Q1-2025 $516.575M ▼ $746.338M ▼ $375.23M ▲ $371.108M ▼
Q4-2024 $588.023M ▼ $782.725M ▼ $355.4M ▲ $427.325M ▼
Q3-2024 $657.067M $827.49M $350.525M $476.965M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-79.115M ▼ $-67.899M ▲ $35.547M ▼ $-1.774M ▼ $-37.71M ▼ $-52.379M ▲
Q2-2025 $-47.92M ▲ $-72.781M ▲ $95.915M ▲ $-768K ▼ $28.081M ▲ $-80.058M ▲
Q1-2025 $-70.161M ▼ $-75.565M ▼ $-59.547M ▲ $0 ▼ $-131.554M ▲ $-83.808M ▼
Q4-2024 $-27.606M ▲ $-37.934M ▲ $-383.589M ▼ $30.007M ▲ $-429.732M ▼ $-61.79M ▲
Q3-2024 $-82.094M $-76.74M $-9.589M $185K $-48.422M $-86.329M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
License
License
 $0 ▲$0 ▲$0 ▲$0 ▲
Product
Product
 $0 ▲$10.00M ▲$20.00M ▲$20.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Autolus is still very much a development‑stage biotech. Revenue has been negligible so far, which means the business is not yet supported by product sales and is instead funded mainly by external capital. Operating losses have been steady and sizable over the past several years, reflecting heavy spending on research, clinical trials, and the build‑out of commercial capabilities. The good news is that the loss per share has been gradually improving over time, suggesting either more disciplined cost control, a broader share base, or both. Still, the overall picture is one of a company investing heavily ahead of meaningful revenue rather than one that is already earning its way.

Balance Sheet

Balance Sheet The balance sheet shows a company that has recently strengthened its financial footing. Total assets and cash reserves have moved up compared with earlier years, indicating fresh capital and a larger resource base to fund development and launch activities. Shareholders’ equity has risen sharply, which typically points to significant new equity issuance and a thicker capital cushion. At the same time, debt levels have climbed from very low to more noticeable, so there is now a mix of equity and borrowing supporting the business. Overall, the company looks better capitalized than in the past, but it is also starting to carry more financial obligations.

Cash Flow

Cash Flow Cash flow remains firmly negative, which is typical for a clinical‑stage biotech transitioning toward commercialization. Operating cash outflows have persisted year after year, showing that the company’s day‑to‑day activities consume cash rather than generate it. Free cash flow is also consistently negative, as modest but steady capital spending adds to the cash burn. This pattern means Autolus is reliant on raising external funds over time to support research, trials, and the commercial ramp of its lead therapy. The key question going forward is how quickly product sales can offset this cash burn trajectory.

Competitive Edge

Competitive Edge Autolus operates in one of the most competitive areas of biotech—cell therapies for cancer and autoimmune disease—but it has carved out some distinct advantages. Its lead product, obe‑cel (AUCATZYL), is designed for a safer and more controlled immune response, and clinical data so far points to fewer severe side effects compared with some existing CAR‑T therapies. Regulatory recognition of this safety profile, including less restrictive safety management requirements, may make it easier for treatment centers to adopt. Autolus also benefits from in‑house manufacturing, which can improve reliability and control in a field where production is complex and time‑sensitive. On the risk side, the company competes against large, well‑funded pharma players with established products, and it must prove it can execute commercially, not just scientifically.

Innovation and R&D

Innovation and R&D Innovation is the core of Autolus’s story. The company has built a modular T‑cell engineering platform aimed at making therapies that are not only potent but also safer and more durable. This includes features like fast‑off rate binding to reduce toxicity, dual‑targeting to limit cancer escape, and programming modules that can be mixed and matched for different diseases. The pipeline goes beyond the initial cancer use of obe‑cel into large autoimmune conditions such as lupus and multiple sclerosis, which, if successful, could dramatically expand the opportunity. Additional programs are targeting multiple myeloma and even solid tumors, areas where current cell therapies face major challenges. All of this requires sustained, heavy R&D spending and carries high clinical risk, but it also underpins Autolus’s potential to be a long‑term innovator rather than a single‑product company.

Summary

Autolus is a high‑risk, high‑innovation cell therapy company that is still early in its commercial journey. Financially, it is characterized by minimal revenue to date, sizable ongoing losses, and persistent negative cash flow, offset by a recently strengthened balance sheet built through equity financing and some added debt. Strategically, its edge lies in a differentiated CAR‑T design with a stronger safety profile, in‑house manufacturing, and a pipeline that extends from blood cancers into major autoimmune diseases. The upside case depends on successful commercial rollout of AUCATZYL and positive data in new indications; the downside centers on execution risk, competitive pressure from large incumbents, and the need for continued external funding until the business becomes more self‑sustaining.

NEWS

November 25, 2025 · 4:00 AM UTC

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

Read more

November 13, 2025 · 4:05 PM UTC

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Read more

November 12, 2025 · 7:00 AM UTC

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Read more

November 3, 2025 · 9:05 AM UTC

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

Read more

October 30, 2025 · 7:00 AM UTC

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Read more